KIORA PHARMACEUTICALS INC KPRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-17.3
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $0 | -$10.8M | — | -$10.1M | $16.1M |
| 2024 | $16.0M | $3.6M | — | $8.6M | $25.8M |
| 2023 | $0 | -$12.5M | — | -$9.6M | $6.1M |
| 2022 | — | -$13.6M | — | -$10.4M | $11.4M |
| 2021 | $0 | -$13.8M | — | -$10.7M | $14.6M |
| 2020 | $12,059 | -$8.1M | — | -$7.3M | $9.7M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -17.3 (distress)
- Working capital / assets 0.747
- Retained earnings / assets -6.359
- EBIT / assets -0.529
- Equity / liabilities 1.984
Source: SEC EDGAR filings · CIK 0001372514 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.